Aslan Pharma signs agreement with CSL to develop novel therapy for asthma

19 May 2014

Singapore-based Aslan Pharmaceuticals has signed a global license agreement to develop an anti-interleukin (IL)13 receptor monoclonal antibody from Australian blood products and vaccine maker CSL Ltd (CSL: AX).

The molecule, CSL334, is currently in preclinical development for the treatment of asthma. Aslan will be responsible for developing CSL334 through clinical proof-of-concept, primarily in Asia. At that time, Aslan will identify a global partner for the Phase III trial and commercialization. CSL will receive a portion of the proceeds, though further financial details were not disclosed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >